TR200103690T2 - IL-8 reseptör antagonistleri - Google Patents

IL-8 reseptör antagonistleri

Info

Publication number
TR200103690T2
TR200103690T2 TR2001/03690T TR200103690T TR200103690T2 TR 200103690 T2 TR200103690 T2 TR 200103690T2 TR 2001/03690 T TR2001/03690 T TR 2001/03690T TR 200103690 T TR200103690 T TR 200103690T TR 200103690 T2 TR200103690 T2 TR 200103690T2
Authority
TR
Turkey
Prior art keywords
receptor antagonists
chemokine
interleukin
formula
treatment
Prior art date
Application number
TR2001/03690T
Other languages
English (en)
Inventor
L. Bryan Deborah
G. Gleason John
L. Widdowson Katherine
M. Benson Gregory
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of TR200103690T2 publication Critical patent/TR200103690T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Bu bulus, yeni formül (I) bilesimleriyle, farmasötik terkipleriyle ve kemokin, interleukin-8(IL-8) kaynakli hastaliklarin tedavisinde kullanimlariyla ilgilidir.
TR2001/03690T 1999-06-16 2000-06-16 IL-8 reseptör antagonistleri TR200103690T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13967499P 1999-06-16 1999-06-16

Publications (1)

Publication Number Publication Date
TR200103690T2 true TR200103690T2 (tr) 2002-05-21

Family

ID=22487784

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03690T TR200103690T2 (tr) 1999-06-16 2000-06-16 IL-8 reseptör antagonistleri

Country Status (22)

Country Link
EP (1) EP1191934A4 (tr)
JP (1) JP2003501471A (tr)
KR (1) KR20020009635A (tr)
CN (1) CN1494424A (tr)
AR (1) AR029368A1 (tr)
AU (1) AU766086B2 (tr)
BR (1) BR0010985A (tr)
CA (1) CA2377397A1 (tr)
CZ (1) CZ20014490A3 (tr)
EC (2) ECSP003525A (tr)
HK (1) HK1044716A1 (tr)
HU (1) HUP0202019A3 (tr)
IL (1) IL146214A0 (tr)
MX (1) MXPA01013287A (tr)
NO (1) NO20016065L (tr)
NZ (1) NZ515232A (tr)
PE (1) PE20010319A1 (tr)
PL (1) PL352218A1 (tr)
TR (1) TR200103690T2 (tr)
UY (1) UY26209A1 (tr)
WO (1) WO2000076516A1 (tr)
ZA (1) ZA200110203B (tr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642215B2 (en) * 2001-05-24 2003-11-04 Leo Pharma A/S Method of modulating NF-kB activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0344425B1 (en) * 1988-03-30 1993-12-08 Warner-Lambert Company N-[[(2,6-disubstituted)phenyl]-N'- arylalkyl] ureas as antihypercholesterolemic and antiatherosclerotic agents
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
AR008290A1 (es) * 1996-08-15 1999-12-29 Smithkline Beecham Corp Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios.

Also Published As

Publication number Publication date
CZ20014490A3 (cs) 2002-07-17
ZA200110203B (en) 2002-09-11
WO2000076516A1 (en) 2000-12-21
MXPA01013287A (es) 2002-06-04
KR20020009635A (ko) 2002-02-01
PE20010319A1 (es) 2001-05-24
UY26209A1 (es) 2000-12-29
JP2003501471A (ja) 2003-01-14
EP1191934A1 (en) 2002-04-03
EP1191934A4 (en) 2004-02-04
ECSP003525A (es) 2002-01-25
NO20016065D0 (no) 2001-12-12
AR029368A1 (es) 2003-06-25
AU5748200A (en) 2001-01-02
HUP0202019A3 (en) 2003-03-28
ECSP003528A (es) 2002-01-25
CA2377397A1 (en) 2000-12-21
HK1044716A1 (zh) 2002-11-01
HUP0202019A2 (en) 2002-10-28
AU766086B2 (en) 2003-10-09
NZ515232A (en) 2004-02-27
PL352218A1 (en) 2003-08-11
IL146214A0 (en) 2002-07-25
CN1494424A (zh) 2004-05-05
NO20016065L (no) 2001-12-12
BR0010985A (pt) 2002-03-26

Similar Documents

Publication Publication Date Title
TR199900318T2 (tr) IL-8 reseptör antagonistleri.
TR199901710T2 (tr) IL-8 reseptör antagonistleri.
YU45293A (sh) Morfolin i tiomorfolin tahikinin antagonisti receptora
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
TR200101772T2 (tr) IL-8 Reseptörü antagonistleri olarak hidroksi difenil üre sülfonamidler
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
ATE250577T1 (de) Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
ATE461196T1 (de) Benzodiazepin-cgrp-rezeptor-antagonisten
BR0110968A (pt) Antagonistas dos receptores de il-8
CY1106514T1 (el) Ανταγωνιστες υποδοχεων il-8
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
DE60230722D1 (de) Il-8-rezeptor-antagonisten
TR200200066T2 (tr) Migrenin tedavisi için seçici iGluR5 reseptör antagonistleri
DE60129154D1 (de) Neuartige verbindungen
SE9902765D0 (sv) Novel compounds
TR199901761T2 (tr) IL-8 reseptör antagonistleri.
TR200103638T2 (tr) IL-8 Reseptör antagonistleri
TR200103448T2 (tr) IL-8 reseptör antagonistleri.
AP1548A (en) Il-8 Receptor Antagonists.
SE9902551D0 (sv) Novel compounds
TR200000610T2 (tr) IL-8 reseptör karşıtları.
DE60015187D1 (de) Urotensin-ii rezeptorantagonisten
AP2002002606A0 (en) INTERLEUKIN 8 RECEPTOR ANTAGONISTS
MY143477A (en) Il-8 receptor antagonists
TR200103354T2 (tr) IL-8 Reseptör antagonistleri